Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Sclafani

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|April 21, 2019
MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the panFrancesco Sclafani
The Lancet. Oncology|July 24, 2017
PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancerFrancesco Sclafani
The Lancet. Oncology|July 26, 2018
Building evidence-based treatment recommendations for advanced anal cancer: the time is nowFrancesco Sclafani
Current Opinion in Oncology|June 17, 2020
Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much betterFrancesco Sclafani, Alain Hendlisz
Future Oncology (London, England)|December 5, 2014
Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancerFrancesco Sclafani, David Cunningham
Current Oncology Reports|May 6, 2018
Systemic Therapies for Advanced Squamous Cell Anal CancerFrancesco Sclafani, Sheela Rao
Seminars in Radiation Oncology|May 31, 2016
Timing of Therapies in the Multidisciplinary Treatment of Locally Advanced Rectal Cancer: Available Evidence and Implications for Routine PracticeFrancesco Sclafani, Ian Chau
Current Opinion in Oncology|July 15, 2022
Editorial: 'All you need is immunotherapy': a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?Francesco Sclafani, Alain Hendlisz
Current Opinion in Oncology|May 9, 2021
Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?Alain Hendlisz, Francesco Sclafani
The Lancet. Oncology|August 5, 2014
Cetuximab or bevacizumab in metastatic colorectal cancer?Francesco Sclafani, David Cunningham
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|April 21, 2019
MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the panFrancesco Sclafani
The Lancet. Oncology|July 24, 2017
PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancerFrancesco Sclafani
The Lancet. Oncology|July 26, 2018
Building evidence-based treatment recommendations for advanced anal cancer: the time is nowFrancesco Sclafani
Current Opinion in Oncology|June 17, 2020
Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much betterFrancesco Sclafani, Alain Hendlisz
Future Oncology (London, England)|December 5, 2014
Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancerFrancesco Sclafani, David Cunningham
Current Oncology Reports|May 6, 2018
Systemic Therapies for Advanced Squamous Cell Anal CancerFrancesco Sclafani, Sheela Rao
Seminars in Radiation Oncology|May 31, 2016
Timing of Therapies in the Multidisciplinary Treatment of Locally Advanced Rectal Cancer: Available Evidence and Implications for Routine PracticeFrancesco Sclafani, Ian Chau
Current Opinion in Oncology|July 15, 2022
Editorial: 'All you need is immunotherapy': a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?Francesco Sclafani, Alain Hendlisz
Current Opinion in Oncology|May 9, 2021
Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?Alain Hendlisz, Francesco Sclafani
The Lancet. Oncology|August 5, 2014
Cetuximab or bevacizumab in metastatic colorectal cancer?Francesco Sclafani, David Cunningham
Pageof 12